Clinical trial
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid…
NCT00402558 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00402558 |
|---|---|
| Title | Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) |
| Official title | Alloreactive NK Cells With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for AML and MDS |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | Thymoglobulin, Busulfan, Fludarabine, Alloreactive NK Infusion, G-CSF, Tacrolimus, Methotrexate, Interleukin-2 |
| Enrollment | 15 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2014 |
| Completion | Apr 1, 2014 |
| First posted | Nov 22, 2006 |
| Last update posted | May 8, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: